Trials / Not Yet Recruiting

Not Yet RecruitingNCT06218888

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Status: Not Yet Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 17 (estimated)

Sponsor: Fujian Cancer Hospital · Other Government
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Not accepted

Summary

To explore the Efficacy and Safety of Tislelizumab combined with fruquintinib and Chidamide in the treatment of unresectable or advanced microsatellite stabilized (MSS/pMMR) colorectal cancer with liver metastases

Conditions

Colo-rectal Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	Tislelizumab 200mg，D1, Q3W
DRUG	Fruquintinib	Fruquintinib 3mg ,D1-D14, Q3W
DRUG	Chidamide	Chidamide 30mg

Timeline

Start date: 2024-06-01
Primary completion: 2025-12-01
Completion: 2026-12-01
First posted: 2024-01-23
Last updated: 2024-01-23

Source: ClinicalTrials.gov record NCT06218888. Inclusion in this directory is not an endorsement.